2024年，出海依然是生物医药产业的关键词。ADC、双抗药物合作交易火爆，出海数量再创新高；交易金额上限不断突破，多家药企凭借出海扭亏为盈。 海外市场为生物医药产业带来了新的增量和发展方向，但走好出海之路绝非易事。近年来，创新药海外合作数量上升的同时，也有部分合作半路终止。此外，还有企业受地缘政治等因素影响，割舍或是调整海外业务。 不过，好在各方都没有放弃，而是积极探索出新的道路。“NewCo...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.